Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famciclovir for EBV Shedding in MS
NCT05283551Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famciclovir in multiple sclerosis (MS), sponsored by Queen Mary University of London. Primary endpoint: Effect of famciclovir on Epstein-Barr virus (EBV) shedding at 36 weeks. Status: unknown.
02
Drugs
famciclovir
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05283551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283551.